文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换术后运动能力变化的预测因素及其与临床结局的关联

Predictors and Association With Clinical Outcomes of the Changes in Exercise Capacity After Transcatheter Aortic Valve Replacement.
PubMed 文献 · Circulation · 2017-06-06

本研究纳入305例接受TAVR的患者,在基线和术后6个月完成6分钟步行试验(6MWT),比较步行距离变化≥中位数百分比(改善组)与<中位数百分比(未改善组)的临床结局。结果显示约三分之一患者术后运动能力未改善,未改善与全因死亡及心血管死亡或再住院独立相关,基线及围术期因素可预测运动能力改善不足。

要点

  • 6MWT改善不足20%与全因死亡及心血管死亡或再住院独立相关。
  • 高龄、女性、COPD、围术期出血及新发贫血预测运动能力改善不足。

核心结论

  • 约三分之一TAVR患者术后6个月运动能力未改善,未改善与较差临床结局独立相关。
  • 系统评估TAVR术前和术后运动能力可能有助于改善患者风险分层。

研究设计与样本

  • 前瞻性队列研究,纳入305例接受TAVR并完成基线和术后6个月6MWT评估的患者。
  • 平均年龄79±9岁,男性44%,STS预测风险死亡率6.7±4.2%。
  • 按6MWT距离变化百分比高于(n=152)或低于(n=153)中位数分为改善组和未改善组。

主要发现

  • TAVR术前和术后6个月平均6MWT距离分别为204±119米和263±116米,平均变化60±106米。
  • 219例(72%)患者步行距离增加,总体中位百分比增加20%(IQR 0%-80%)。
  • 未改善组与改善组相比,全因死亡(P=0.002)和心血管死亡或再住院(P=0.001)风险显著增高。
  • 基线慢步行者中,6MWT距离改善者较未改善者全因死亡(P=0.01)和心血管终点(P=0.001)结局更优。

关键数值与推荐

  • 6MWT距离变化百分比≥20%为改善阈值,不足20%与全因死亡(P=0.002)及心血管死亡或再住院(P=0.001)独立相关。
  • 与运动能力改善不足独立相关的因素包括高龄、女性、COPD(P<0.05)、围术期大或危及生命出血(P=0.009)及术后6个月新发贫血(P=0.009)。

临床怎么用

  • TAVR术前和术后6个月应系统评估6MWT,识别运动能力改善不足的高风险患者。
  • 对高龄、女性、COPD、围术期出血或术后新发贫血患者,应加强术后康复和随访。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At present, there are no objective data specifically examining the clinical impact of variations in exercise capacity post-transcatheter aortic valve replacement (TAVR). We describe the changes in exercise capacity between baseline and 6 months post-TAVR, and ascertain factors associated with and clinical implications of a lack of improvement in exercise capacity post-TAVR. METHODS: A total of 305 patients (mean age, 79±9 years; 44% men; Society of Thoracic Surgeons predicted risk mortality score, 6.7±4.2%) undergoing TAVR completed both baseline and follow-up exercise capacity assessments at 6 months post-TAVR. Exercise capacity was evaluated by the 6-minute walk test (6MWT). Clinical outcomes were compared between patients displaying greater than (n=152; improving group) versus less than (n=153; nonimproving group) the median percentage change in distance walked between baseline and 6-month follow-up examinations. The primary outcome measure was clinical event rates, measured from the 6-month post-TAVR period onward. Further dichotomization according to baseline 6MWT distance (less than versus more than median walking distance, or slow walker versus fast walker) was also assessed. RESULTS: The mean overall distances walked pre- and post-TAVR (6 months post-TAVR) were 204±119 and 263±116 m, respectively (Δ6MWT=60±106 m), with 219 (72%) patients demonstrating an increase in their walking distance (median percentage increase of the entire population was 20% [interquartile range, 0%-80%]). Factors independently correlated with reduced exercise capacity improvement included a range of baseline clinical characteristics (older age, female sex, chronic obstructive pulmonary disease; P<0.05 for all), periprocedural major or life-threatening bleeding (P=0.009) and new-onset anemia at 6 months post-TAVR (P=0.009). Failure to improve the 6MWT distance by at least 20% was independently associated with all-cause mortality (P=0.002) and cardiovascular death or rehospitalization for cardiovascular causes (P=0.001). Baseline slow walkers who were able to improve the 6MWT distance presented with significantly better outcomes than nonimprovers (P=0.01 for all-cause mortality; P=0.001 for cardiovascular end point). CONCLUSIONS: Approximately one-third of patients undergoing TAVR did not improve their exercise capacity postprocedure. The lack of functional improvement post-TAVR was predicted by a mix of baseline and periprocedural factors translating into poorer clinical outcomes. These results suggest that systematically implementing exercise capacity assessment pre- and post-TAVR may help to improve patient risk stratification.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Abdul-Jawad Altisent O, Puri R, Regueiro A, et al. Predictors and Association With Clinical Outcomes of the Changes in Exercise Capacity After Transcatheter Aortic Valve Replacement. Circulation. 2017. PMID: 28588077. doi:10.1161/CIRCULATIONAHA.116.026349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。